CA2674538C - An insulinotropic complex using an immunoglobulin fragment - Google Patents

An insulinotropic complex using an immunoglobulin fragment Download PDF

Info

Publication number
CA2674538C
CA2674538C CA2674538A CA2674538A CA2674538C CA 2674538 C CA2674538 C CA 2674538C CA 2674538 A CA2674538 A CA 2674538A CA 2674538 A CA2674538 A CA 2674538A CA 2674538 C CA2674538 C CA 2674538C
Authority
CA
Canada
Prior art keywords
group
insulinotropic peptide
exendin
immunoglobulin
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2674538A
Other languages
English (en)
French (fr)
Other versions
CA2674538A1 (en
Inventor
Dae Hae Song
Chang Ki Lim
Tae Hun Song
Young Hoon Kim
Se Chang Kwon
Gwan Sun Lee
Sung Youb Jung
In Young Choi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Science Co Ltd
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of CA2674538A1 publication Critical patent/CA2674538A1/en
Application granted granted Critical
Publication of CA2674538C publication Critical patent/CA2674538C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA2674538A 2007-01-05 2008-01-04 An insulinotropic complex using an immunoglobulin fragment Active CA2674538C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2007-0001662 2007-01-05
KR20070001662 2007-01-05
PCT/KR2008/000061 WO2008082274A1 (en) 2007-01-05 2008-01-04 An insulinotropic complex using an immunoglobulin fragment

Publications (2)

Publication Number Publication Date
CA2674538A1 CA2674538A1 (en) 2008-07-10
CA2674538C true CA2674538C (en) 2013-12-17

Family

ID=39588830

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2674538A Active CA2674538C (en) 2007-01-05 2008-01-04 An insulinotropic complex using an immunoglobulin fragment

Country Status (20)

Country Link
US (1) US8476230B2 (enExample)
EP (1) EP2114438B8 (enExample)
JP (2) JP2008169195A (enExample)
KR (3) KR101058290B1 (enExample)
CN (3) CN103435700B (enExample)
AR (2) AR065639A1 (enExample)
AU (1) AU2008203574B2 (enExample)
BR (1) BRPI0806262A2 (enExample)
CA (1) CA2674538C (enExample)
DK (1) DK2114438T3 (enExample)
ES (1) ES2394121T3 (enExample)
IL (1) IL199566A (enExample)
MX (1) MX2009007267A (enExample)
MY (1) MY164479A (enExample)
NZ (1) NZ577812A (enExample)
PT (1) PT2114438E (enExample)
RU (1) RU2436589C2 (enExample)
TW (1) TWI413528B (enExample)
WO (1) WO2008082274A1 (enExample)
ZA (1) ZA200904337B (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
US8110665B2 (en) * 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
JP2009019027A (ja) * 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
RU2483081C2 (ru) * 2008-07-23 2013-05-27 Ханми Сайенс Ко.,Лтд.,Kr Полипептидный комплекс, содержащий непептидильный полимер, обладающий тремя функциональными концами
EP2416797A4 (en) 2009-04-10 2013-04-24 Amylin Pharmaceuticals Llc AMYLINAGONIST COMPOUNDS FOR OXYGEN ANIMAL MICE
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
EP2504021A4 (en) 2009-11-23 2013-05-15 Amylin Pharmaceuticals Llc Polypeptide conjugate
PL2865751T3 (pl) * 2010-03-02 2017-03-31 Protalix Ltd Stabilizowana alfa-galaktozydaza i jej zastosowania
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
KR101324828B1 (ko) * 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
JP6121330B2 (ja) 2010-09-28 2017-04-26 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続時間が増した改変ポリペプチド
CA2813087C (en) 2010-09-28 2020-07-21 Amylin Pharmaceuticals, Llc Engineered polypeptides having enhanced duration of action
WO2012162547A2 (en) 2011-05-25 2012-11-29 Amylin Pharmaceuticals, Inc. Long duration dual hormone conjugates
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
PH12018501954A1 (en) 2011-06-10 2023-02-13 Hanmi Science Co Ltd Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
RU2733544C2 (ru) 2011-06-17 2020-10-05 Ханми Сайенс Ко., Лтд. Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение
CN103957926B (zh) 2011-07-08 2018-07-03 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
CN103172745A (zh) * 2011-12-21 2013-06-26 北京韩美药品有限公司 包含免疫球蛋白Fc片段的长效人内皮抑素
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
KR101895047B1 (ko) * 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
KR101665009B1 (ko) * 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
US10441665B2 (en) 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092862A1 (es) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
IN2015DN03795A (enExample) 2012-10-24 2015-10-02 Inserm Inst Nat De La Santé Et De La Rech Médicale
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
EP3610856B1 (en) * 2012-11-06 2021-08-18 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR20140088837A (ko) 2013-01-03 2014-07-11 한미약품 주식회사 Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체
CN104995206B (zh) * 2013-02-26 2022-04-12 韩美药品株式会社 新颖的胰岛素类似物及其用途
KR101895634B1 (ko) * 2013-05-31 2018-09-05 한미약품 주식회사 변이된 힌지 영역을 포함하는 IgG4 Fc 단편
AR096890A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
MA39301A1 (fr) 2014-01-20 2018-01-31 Hanmi Pharmaceutical Co Ltd Insuline à action prolongée et utilisation associée
SG11201608120TA (en) * 2014-03-31 2016-11-29 Hanmi Pharm Ind Co Ltd Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
KR20150140177A (ko) * 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
TWI772252B (zh) 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
US20160151511A1 (en) * 2014-12-02 2016-06-02 Antriabio, Inc. Proteins and protein conjugates with increased hydrophobicity
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
PH12017501222B1 (en) 2014-12-30 2024-07-03 Hanmi Pharmaceutical Co Ltd Glucagon derivatives with improved stability
EP3273981B1 (en) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of diabetes
AR105485A1 (es) 2015-06-30 2017-10-11 Hanmi Pharm Ind Co Ltd Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
WO2017052329A1 (en) * 2015-09-24 2017-03-30 Hanmi Pharm. Co., Ltd. Protein complex by use of a specific site of an immunoglobulin fragment for linkage
TWI807580B (zh) 2015-12-31 2023-07-01 南韓商韓美藥品股份有限公司 三重升糖素/glp-1/gip 受體促效劑
UA126662C2 (uk) 2016-06-29 2023-01-11 Ханмі Фарм. Ко., Лтд. Похідна глюкагону, її кон'югат, композиція, яка її містить, та її терапевтичне застосування
BR112019005637A2 (pt) 2016-09-23 2019-07-30 Hanmi Pharm Ind Co Ltd análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso
JOP20190097A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv الجلوبولينات المناعية واستخداماتها
CN110291103A (zh) 2016-12-05 2019-09-27 韩美药品株式会社 具有弱化的免疫应答的缀合物
EP3578204A4 (en) * 2017-02-03 2021-01-06 Hanmi Pharm. Co., Ltd. BIOACTIVE SUBSTANCE CONJUGATE WITH ENHANCED DURABILITY AND ITS USE
KR101941975B1 (ko) 2017-03-17 2019-01-25 고려대학교 산학협력단 Atpif1을 함유하는 당뇨 치료용 약학조성물
WO2018174668A2 (ko) 2017-03-23 2018-09-27 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
CA3071337A1 (en) 2017-08-15 2019-02-21 Kindred Biosciences, Inc. Igg fc variants for veterinary use
CN111433221B (zh) * 2017-09-28 2024-12-27 韩美药品株式会社 胰高血糖素样肽-2(glp-2)衍生物的长效缀合物
KR20190038456A (ko) 2017-09-29 2019-04-08 한미약품 주식회사 효력이 향상된 지속성 단백질 결합체
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof
KR20230000682A (ko) 2021-06-25 2023-01-03 한미약품 주식회사 심혈관 질환 또는 신장 기능장애 발생의 위험을 감소시키기 위한 에페글레나타이드

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401716A (en) * 1987-04-15 1995-03-28 Semiconductor Energy Laboratory Co., Ltd. Method for manufacturing superconducting patterns
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5424686A (en) 1994-04-20 1995-06-13 Philips Electronics North America Corporation Negative-resistance-compensated microwave buffer
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US7157555B1 (en) * 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6815203B1 (en) * 1999-06-23 2004-11-09 Joslin Diabetes Center, Inc. Methods of making pancreatic islet cells
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
SK288342B6 (en) 2000-12-07 2016-03-01 Lilly Co Eli GLP-1 fusion proteins
KR20040074587A (ko) 2001-02-19 2004-08-25 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 인공 단백질
US7790681B2 (en) * 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
JP2006520818A (ja) * 2003-03-19 2006-09-14 イーライ リリー アンド カンパニー ポリエチレングリコール結合ｇｌｐ−１化合物
DK1641823T3 (da) 2003-06-12 2011-12-12 Lilly Co Eli GLP-1-analog fusionsproteiner
DE10352479A1 (de) * 2003-11-07 2005-06-09 Basf Ag Verfahren zur Herstellung von Polymerisatpulvern aus wässrigen Polymerisatdispersionen
US7736653B2 (en) 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Pharmaceutical composition comprising an immunoglobulin Fc region as a carrier
JP2006514649A (ja) * 2003-12-17 2006-05-11 アミリン・ファーマシューティカルズ，インコーポレイテッド 腎症の治療および予防のための組成物
KR20060109940A (ko) 2003-12-18 2006-10-23 노보 노르디스크 에이/에스 알부민-유사제에 연결된 신규 ｇｌｐ-1 유사체
JP2008507280A (ja) * 2004-07-21 2008-03-13 アンブレツクス・インコーポレイテツド 非天然コードアミノ酸を用いた生合成ポリペプチド
MX2007007565A (es) * 2004-12-22 2007-07-24 Lilly Co Eli Formulaciones de proteina de fusion analoga del peptido-1similar al glucagon (glp-1).
US20080207505A1 (en) 2005-01-12 2008-08-28 James Kenneth D Bna Conjugates and Methods of Use
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
BRPI0609676A2 (pt) 2005-05-13 2011-10-18 Lilly Co Eli composto de glp-1 peguilado,e, uso do mesmo

Also Published As

Publication number Publication date
PT2114438E (pt) 2012-10-11
CN103435700B (zh) 2015-12-23
HK1136504A1 (en) 2010-07-02
CN103435699A (zh) 2013-12-11
MY164479A (en) 2017-12-29
RU2009129953A (ru) 2011-02-10
JP2008169195A (ja) 2008-07-24
DK2114438T3 (da) 2012-12-17
AR065639A1 (es) 2009-06-17
KR20100061786A (ko) 2010-06-09
KR101058315B1 (ko) 2011-08-22
CN103435699B (zh) 2015-04-15
KR101058290B1 (ko) 2011-08-22
EP2114438A4 (en) 2010-09-01
IL199566A (en) 2016-09-29
EP2114438B1 (en) 2012-08-29
CN101646451A (zh) 2010-02-10
CN101646451B (zh) 2014-03-26
CA2674538A1 (en) 2008-07-10
BRPI0806262A2 (pt) 2011-08-30
CN103435700A (zh) 2013-12-11
TWI413528B (zh) 2013-11-01
WO2008082274A1 (en) 2008-07-10
AR110853A2 (es) 2019-05-08
ZA200904337B (en) 2010-10-27
AU2008203574A1 (en) 2008-07-10
EP2114438B8 (en) 2012-10-03
US20100105877A1 (en) 2010-04-29
EP2114438A1 (en) 2009-11-11
MX2009007267A (es) 2009-11-11
TW200930408A (en) 2009-07-16
KR20110092253A (ko) 2011-08-17
ES2394121T3 (es) 2013-01-21
NZ577812A (en) 2012-01-12
AU2008203574B2 (en) 2011-12-01
RU2436589C2 (ru) 2011-12-20
JP5399265B2 (ja) 2014-01-29
KR20080064750A (ko) 2008-07-09
JP2010515677A (ja) 2010-05-13
US8476230B2 (en) 2013-07-02

Similar Documents

Publication Publication Date Title
CA2674538C (en) An insulinotropic complex using an immunoglobulin fragment
US20080124347A1 (en) Insulinotropic peptide conjugate using carrier substance
AU2012263098B2 (en) Composition for treating diabetes comprising long-acting insulin conjugate and long-acting insulinotropic peptide conjugate
US20090238838A1 (en) Insulinotropic peptide conjugate using an immunoglobulin fc
EP3248611B1 (en) Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity
JP6336394B2 (ja) 生理活性ポリペプチド複合体の製造方法
WO2008136611A1 (en) Natriuretic peptide conjugate using carrier substance
CA2795291A1 (en) An insulin conjugate using an immunoglobulin fragment
KR20140058104A (ko) 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
KR20170100908A (ko) 지속형 fgf21 수용체 아고니스트 결합체 및 지속형 인슐린 분비 펩타이드 결합체를 포함하는 대사증후군 치료용 조성물
HK1136504B (en) An insulinotropic complex using an immunoglobulin fragment

Legal Events

Date Code Title Description
EEER Examination request